Adrenergic receptor blockade-induced regression of pressure-overload cardiac hypertrophy is associated with inhibition of the calcineurin/NFAT3/GATA4 pathway

Molecular Medicine Reports

Volumn 3, Issue 3, 2010, Pages 497-501

  Yang, Dachun ^a   Ma, Shuangtao ^a   Tan, Yan ^a   Li, D E ^a   Tang, Bing ^a   Chen, Jinsong ^a   Su, Xiaohua ^a   Li, Gang ^a   Zhang, Xin ^a   Yang, Yongjian ^a  

^a General Hospital of PLA Chengdu Military Area Command   (China)

Author keywords

Calcineurin; Carvedilol; Metoprolol; Nuclear factor of activated t cells 3; Zinc finger containing transcription factor

Indexed keywords

ADRENERGIC RECEPTOR; CALCINEURIN; CARVEDILOL; METOPROLOL; MYC PROTEIN; TERAZOSIN; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NFAT3;

ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; ATTENUATION; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFICACY; HEART HEMODYNAMICS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR UPREGULATION; SHAM PROCEDURE; SIGNAL TRANSDUCTION; SYMPATHETIC TONE; TRANSCRIPTION INITIATION;

RATTUS;

EID: 77952403430     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000287     Document Type: Article

References (28)

1. Sakata Y, Masuyama T, Yamamoto K, Nishikawa N, Yamamoto H, Kondo H, Ono K, Otsu K, Kuzuya T, Miwa T, Takeda H, Miyamoto E and Hori M: Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation 102: 2269-2275, 2000.
2. Wagoner LE and Walsh RA: The cellular pathophysiology of progression to heart failure. Curr Opin Cardiol 11: 237-244, 1996. (Pubitemid 26238070)
3. Haq S, Choukroun G, Lim H, Tymitz KM, Del Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T and Molkentin JD: Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 103: 670-677, 2001.
4. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR and Olson EN: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93: 215-228, 1998. (Pubitemid 28180855)
5. Ritter O, Hack S, Schuh K, Rothlein N, Perrot A, Osterziel KJ, Schulte HD and Neyses L: Calcineurin in human heart hypertrophy. Circulation 105: 2265-2269, 2002.
6. Zhang W: Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy. Cardiovasc Res 53: 294-303, 2002.
7. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, Colbert MC, Gualberto A, Wieczorek DF and Molkentin JD: Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 281: 1690-1693, 1998. (Pubitemid 28435588)
8. Walsh RA: Calcineurin inhibition as therapy for cardiac hypertrophy and heart failure: requiescat in pace? Circ Res 84: 741-743, 1999.
9. Luo Z, Shyu KG, Gualberto A and Walsh K: Calcineurin inhibitors and cardiac hypertrophy. Nat Med 4: 1092-1093, 1998.
10. Force T, Rosenzweig A, Choukroun G and Hajjar R: Calcineurin inhibitors and cardiac hypertrophy. Lancet 353: 1290-1292, 1999.
11. Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN and Vatner SF: Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res 84: 735-740, 1999. (Pubitemid 29157342)
12. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T and Suthanthiran M: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397: 530-534, 1999. (Pubitemid 129623673)
13. Palazzesi S, Musumeci M, Catalano L, Patrizio M, Stati T, Michienzi S, Di Certo MG, Mattei E, Vitelli L and Marano G: Pressure overload causes cardiac hypertrophy in beta1-adrenergic and beta2-adrenergic receptor double knockout mice. J Hypertens 24: 563-571, 2006.
14. Balke CW and Shorofsky SR: Alterations in calcium handling in cardiac hypertrophy and heart failure. Cardiovasc Res 37: 290-299, 1998.
15. Molkentin JD: Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res 87: 731-738, 2000.
16. Zou Y, Hiroi Y, Uozumi H, Takimoto E, Toko H, Zhu W, Kudoh S, Mizukami M, Shimoyama M, Shibasaki F, Nagai R, Yazaki Y and Komuro I: Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation 104: 97-101, 2001. (Pubitemid 32623296)
17. Yang D, Ma S, Li D, Tang B and Yang Y: Angiotensin II receptor blockade improves matrix metalloproteinases/tissue inhibitor of matrix metalloproteinase-1 balance and restores fibronectin expression in rat infarcted myocardium. Biochem Biophys Res Commun 388: 606-611, 2009.
18. Shimoyama M, Hayashi D, Takimoto E, Zou Y, Oka T, Uozumi H, Kudoh S, Shibasaki F, Yazaki Y, Nagai R and Komuro I: Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 100: 2449-2454, 1999.
19. Lim HW, De Windt LJ, Steinberg L, Taigen T, Witt SA, Kimball TR and Molkentin JD: Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. Circulation 101: 2431-2437, 2000. (Pubitemid 30329136)
20. Eto Y, Yonekura K, Sonoda M, Arai N, Sata M, Sugiura S, Takenaka K, Gualberto A, Hixon ML, Wagner MW and Aoyagi T: Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training. Circulation 101: 2134-2137, 2000.
21. Hayashida W, Kihara Y, Yasaka A and Sasayama S: Cardiac calcineurin during transition from hypertrophy to heart failure in rats. Biochem Biophys Res Commun 273: 347-351, 2000. (Pubitemid 30426909)
22. Ding B, Price RL, Borg TK, Weinberg EO, Halloran PF and Lorell BH: Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res 84: 729-734, 1999. (Pubitemid 29157341)
23. Azevedo ER, Kubo T, Mak S, Al-Hesayen A, Schofield A, Allan R, Kelly S, Newton GE, Floras JS and Parker JD: Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation 104: 2194-2199, 2001.
24. Spinale FG, Johnson WS, Wang Y, Wang Z, Mukherjee R, Hebbar L and Jones BU: Direct effects of chronic beta-adrenergic receptor blockade on left ventricular and myocyte function in a model of tachycardia-induced congestive heart failure. J Card Fail 2: 311-318, 1996.
25. Asai T, Kushiro T, Fujita H and Kanmatsuse K: Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction. Hypertens Res 28: 79-87, 2005.
26. Liao Y, Asakura M, Takashima S, Ogai A, Asano Y, Shintani Y, Minamino T, Asanuma H, Sanada S, Kim J, Kitamura S, Tomoike H, Hori M and Kitakaze M: Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 110: 692-699, 2004.
27. Tamai J, Hori M, Kagiya T, Iwakura K, Iwai K, Kitabatake A, Watanabe Y, Yoshida H, Inoue M and Kamada T: Role of alpha 1-adrenoceptor activity in progression of cardiac hypertrophy in guinea pig hearts with pressure overload. Cardiovasc Res 23: 315-322, 1989. (Pubitemid 19104301)
28. Akers WS, Cross A, Speth R, Dwoskin LP and Cassis LA: Renin-angiotensin system and sympathetic nervous system in cardiac pressure-overload hypertrophy. Am J Physiol Heart Circ Physiol 279: H2797-H2806, 2000.